Slide 1: Business Combination with Tenzing Acquisition Corp.
Reviva Pharmaceuticals, Inc. Business Combination with Tenzing Acquisition Corp. (NASDAQ: TZAC/TZACW) October 2020 Confidential
Slide 2: Disclaimer and Other Important Information
Disclaimer and Other Important Information Disclaimer and Other Important Information This presentation (the “Presentation”) is for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination between T
Slide 3: Transaction Overview – 1/2
1. See slide 8 for details and assumptions ; assuming no redemptions by Tenzing shareholders and assuming no other equity issuances by Tenzing . 2. Assumes $ 34 . 4 million in primary funding from cash in trust and no redemptions from Tenzing public shareholders ; excludes approximately 6 . 9 mm out
Slide 4: Transaction Overview – 2/2: Ownership, Management & Governance
Ownership • Current Reviva equity holders r olling 100 % of equity in exchange for approximately 5 . 8 mm shares valued at $ 62 . 4 million 1 • Reviva shareholders will have the ability to earn an additional 1 . 0 mm shares after the closing, if a stock price milestone ( $ 15 . 00 per share for any
Slide 5: Leadership and Board
Leadership and Board Board of Directors Current/Previous Affiliation Parag Saxena 1 (Chairman) Laxminarayan Bhat, PhD (CEO) Les Funtleyder , MPH 1 Richard Margolin, MD 1 Purav Patel 1. At closing of Merger with Tenzing . Other Senior Management Current/Previous Affiliation Marc Cantillon, MD (Chief
Slide 6: Board of Advisors
Board of Advisors 1 Current/Previous Affiliation Daphne Karydas John M. Kane, MD Senior Vice President, Behavioral Health Services, Northwell Health Chair, Psychiatry, Zucker Hillside Hospital Chair, Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Leslie Citrome , MD, M
Slide 7: Financing & Transaction Structure
Financing & Transaction Structure 7
Slide 8: Transaction Overview: Pro Forma Equity Ownership
Reviva Rollover Shareholders 52.1% Public Shareholders 28.8% Tenzing Sponsor 19.1% Transaction Overview Pro Forma Equity Ownership 2 3 4 1. Based on $ 34 . 4 million cash in trust and 3 , 184 , 368 public shares outstanding . 2. Excludes Reviva’s outstanding options and warrants to acquire capital s
Slide 9: Current Financing Round & Use of Proceeds
Current Financing Round & Use of Proceeds 1. Projected amounts for debt financing and licensing deals based on estimates and goals of Reviva management . Such figures are based on assumptions and not on contractual terms and, therefore, are inherently uncertain, and no assurance can be given regardi
Slide 10: Comparable Companies in Neuroscience Space
Comparable Companies in Neuroscience Space 1. Reviva : post Merger with Tenzing - assuming no redemptions by Tenzing shareholders and assuming no other equity issuances by Tenzing . 2. See slide 8 for details and assumptions ; assuming no redemptions by Tenzing shareholders and assuming no other equ
Slide 11: R&D Focus and Product Pipeline
R&D Focus and Product Pipeline 11
Slide 12: Product Pipeline: Overview
Product Pipeline: Overview Therapeutic Areas of Focus ▪ Focused on development of next generation Platform Therapies using chemical genomics driven discovery approach and proprietary drug molecules ▪ Therapeutic areas of focus are the CNS, inflammatory and cardiometabolic diseases ▪ Company has 2 ne
Slide 13: Clinical Development of Brilaroxazine (RP5063)
Clinical Development of Brilaroxazine (RP5063) Neuropsychiatric and Pulmonary Diseases Neuropsychiatric Diseases Pulmonary Diseases • Schizophrenia (ready for phase 3) • Pulmonary Arterial Hypertension (ready for phase 2) • Bipolar Disorder (ready for phase 2) • Idiopathic Pulmonary Fibrosis (ready
Slide 14: U.S. Regulatory Status
U.S. Regulatory Status Successful End of Phase 2 (EOP2) meeting with U.S. FDA FDA guidance for p otential “Superior Safety” label claim FDA waived the requirement of CYP2D6 drug interaction clinical study FDA reviewed the phase 3 protocol, CMC, and long - term toxicology package ▪ New chemical entit
Slide 15: Prevalence
15 Prevalence • Schizophrenia : Worldwide prevalence of schizophrenia is approximately 1 . 1 % regardless of racial, ethnic or economic background, with approximately 3 . 5 million people diagnosed in the US . 1 , 2 • Bipolar Disorder : Global prevalence of bipolar spectrum disorders is approximatel
Slide 16: Why Are New Antipsychotics Needed for Schizophrenia
1. Suboptimal efficacy for residual symptoms 1 2 • Negative symptoms • Cognitive deficits • Mood symptoms 2. Poor tolerability / High Side effects 2 • Neurological (EPS, akathisia) • Metabolic (obesity, diabetes, cholesterol) • Endocrine (sexual dysfunction) 3 . High Discontinuation / Non - complian
Slide 17: Brilaroxazine Phase 1B Clinical Study in Stable Schizophrenia
x Cognition improvement supported by pharmacology profile, and translational studies data in rodents 2 1. Cantillon M. et al. Clinical & Translational Science 2018, 11: 387 - 396. 2. Rajagopal, L. et al. Behavioral Brain Research 2017, 332: 180 - 199. Improvement in Cognition Trails A & B Data Decre
Slide 18: Phase 2 Clinical Data for Acute Schizophrenia
Efficacy for Schizophrenia (PANSS reduction: – 20 points) Decrease in Positive Symptoms (PANSS) Improvement in Social Functioning (PANSS) Decrease in Negative Symptoms (PANSS) Cantillon, M. et al. Schizophrenia Research 2017, 189: 126 - 133 Brilaroxazine (RP5063) Phase 2 Clinical Data for Acute Schi
Slide 19: Extremely Clean Side Effect Profile
CNS / Neuroleptic Side Effects Endocrine Side Effects Metabolic Side Effects Brilaroxazine (RP5063) has an Extremely Clean Side Effect Profile Neuroleptic, Endocrine and Metabolic Side Effects Comparable to Placebo Cantillon, M. et al. Schizophrenia Research 2017, 189: 126 - 133 19 Extrapyramidal Si
Slide 20: Therapeutic Benefits
Therapeutic Benefits • Safety data from Reviva’s Phase 2 study for RP 5063 in acute schizophrenia and schizoaffective patients did not reveal any serious and unexpected adverse events . The most common adverse events were insomnia and agitation . RP 5063 showed lower discontinuation rate than placeb
Slide 21: Brilaroxazine vs Standard of Care Antipsychotics
Brilaroxazine vs Standard of Care Antipsychotics Antipsychotic Schizophrenia Bipolar Disorder BD - I BD - II MDD Brilaroxazine (RP5063)* 2 x x x x Olanzapine x x X X Risperidone x x X X Quetiapine x x x x Aripiprazole x x X Lurasidone x x x X Brexpiprazole x X X * In Clinical Development x = First -
Slide 22: Overview of Brilaroxazine Respiratory Programs
• A novel MOA, potentially disease modifying therapy for PAH and IPF • A new chemical entity (NCE) with granted U.S. and European patents • Clinical phase 2 study stage programs for PAH and IPF : x Generally well - tolerated in the phase 1B and phase 2 studies for schizophrenia in >250 patients x Co
Slide 23: PAH and IPF Prevalence and Unmet Need
PAH IPF • Global prevalence of PAH is estimated 6 . 6 – 26 . 0 cases per million with 1 . 1 – 7 . 6 incidences per million adults per year . 1 • PAH is frequently diagnosed in older patients, i . e . 65 years and older . PAH occurs 3 - 5 times more frequently in females as in males, and it tends to
Slide 24: Pathophysiology of PAH and IPF
Pathophysiology of PAH and IPF: • Lung vascular/alveoli remodeling due to inflammation, proliferation of fibrosis, and microthrombi/blood clots, and pulmonary hypertension are morphological hallmarks in patients with PAH and IPF Pathobiology of PAH and IPF: • Elevated plasma serotonin (5 - HT) level
Slide 25: Pharmacologic Activity for PAH in Rodent Models
Treatment Effects on PAH Treatment Effects on Lung Vascular Structure A: PLs in SuHx - only B: PLs in SuHx + RP5063 RP5063 Mitigates Inflammation x Brilaroxazine significantly reduced inflammatory cytokines TNF , IL - β , IL - 6, and chemokine LTB4 Bhat and Salvail, J Rare Dis Res Treat 2017, 2(5):
Slide 26: Mitigates Lung Fibrosis and Inflammation in IPF
RP5063 Mitigates lung fibrosis/collagen (Decrease in Hydroxyproline) Increase in hydroxyproline is an indicator of collagen deposition which is an underlying pathophysiology in IPF Brilaroxazine, as an adjunct to nintedanib and pirfenidone, significantly augmented the functional effects of nintedani
Slide 27: Improves Survival Rate in IPF
Bhat et al., European J Pharmacology 2019 (in peer review) Mitigates Respiratory Resistance Improves Oxygen Saturation Improves Survival Rate Brilaroxazine (RP5063) Improves Survival Rate in IPF Bleomycin (BLM) Induced IPF Rodent Model 27
Slide 28: Translational Data for PAH & IPF
Brilaroxazine’s Translational Data for PAH & IPF x Mitigation of pulmonary hypertension x Mitigation of vascular / alveoli fibrosis x Mitigation of thrombus / blood clot x Mitigation of lung inflammation x Mitigation of respiratory resistance x Improvement in oxygen saturation x Improvement in survi